- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01782170
Efficacy of Iocide Oral Rinse Against Gingival Inflammation
August 13, 2013 updated by: Biomedical Development Corporation
Phase II Study: Evaluate Efficacy of Iocide Oral Rinse in a Human Clinical Trial of Gingival Inflammation and Investigate Effects on Biological Markers Indicative of Systemic Disease
The purpose of this study is to explore the efficacy of Iocide oral rinse in a human clinical trial of gingivitis.
Iocide oral rinse will be evaluated against a placebo rinse.
Indices for gingivitis, plaque and bleeding will be scored and blood tests will be performed to determine the effect of the antimicrobial oral rinse on relative levels of biological markers of inflammation.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
76
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hailey Gallivan, CCRP
- Phone Number: 859-323-4923
- Email: hbwils00@uky.edu
Study Contact Backup
- Name: Karl McCloskey
- Phone Number: (361) 442-7491
- Email: mccloskey@biodevcorp.com
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40506
- Recruiting
- University of Kentucky, Center for Oral Health Research, College of Dentistry
-
Principal Investigator:
- Dolph Dawson, DMD, MS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects shall meet all of the following inclusion criteria to be eligible for participation in this study:
- Males or non-pregnant females of at least 18 years of age, and in good general health, as determined by Investigator;
- Have at least 16 natural, gradable teeth and good dental health, as determined by Investigator;
- Have > 25% sites with Gingival Index (GI) scores of > 2 at Visits 1 and 2;
- Have Plaque Index (PI) scores of > 1 on > 50% of sites;
- Use of effective method of contraception for the duration of the study or permanently sterilized;
- Able and willing to comply with study requirements including following instructions on study treatment and returning for follow-up visits as required by the protocol;
- Have full understanding of all elements of, and signature and dating of the written informed consent prior to the initiation of protocol specified procedures;
- Females with childbearing potential must have a negative pregnancy test before and during the study period. Sexually active females must be using an effective form of birth control or abstinence. These methods include oral contraceptives ("the pill"), an intrauterine device (IUD), levonogestrol implants (Norplant®), medroxyprogesterone acetate injections (Depo-provera®) or contraceptive foam with a condom.
Exclusion Criteria:
Subjects meeting any of the following exclusion criteria will not be eligible for participation in this study:
- History, or current evidence, of any significant acute or chronic subject-reported medical or psychiatric condition that, in the opinion of the Investigator, would render examination difficult or invalid or prevent the subject from active study participation;
- ≤24% of sites with GI score >2;
- Thyroid peroxidase antibody (TPOab) positive >34;
- Screening serum level of thyroid stimulating hormone (TSH) <0.45 or >4.5;
- Treatment with antibiotic within the one (1) month period prior to the screening examination;
- History of heart murmur, history of rheumatic fever, valvular disease, prosthetic implant or any other condition requiring antibiotic premedication;
- History of thyroid disease;
- Purported sensitivity or allergy to iodine;
- Known sensitivity or allergy to shellfish;
- History of diabetes;
- History of autoimmune disease;
- Gross oral pathology (periodontal disease, rampant caries, tissue damage created by poor oral care or treatment, soft or hard tissue tumors) that, in the opinion of the Investigator, could influence the outcome of the study;
- True periodontal pockets of > 5 mm and/or visible recession indicative of attachment loss;
- Current signs or symptoms of mucosal tissue ulcerations or inflammation, or canker sores;
- Presence of orthodontic appliances or any removable appliance that impinges on the oral tissues being assessed;
- History of early onset periodontal disease or acute necrotizing ulcerative gingivitis;
- Subject reported history in past 6 months or current alcohol abuse that, in the opinion of the Investigator, could influence the outcome of the study;
- Subject reported history of last past 6 months or current drug abuse;
- Chronic treatment (2 weeks or more) with any medication known to affect periodontal status (including phenytoin, calcium antagonists, cyclosporine, coumarin, non-steroidal antiinflammatory drugs, and aspirin) within 1 month of the screening examination. All other medications for chronic medical conditions have been initiated at least 3 months before enrollment;
- Current use of a statin or the use of a statin within the past sixty (60) days of screening;
- Concomitant therapy with another investigational drug or device without prior approval from the Sponsor within four weeks prior to Visit 2 (Study Day 1);
- Concomitant endodontic or periodontal therapy other than prophylaxis in the past six (6) months;
- Females with childbearing potential with a positive pregnancy test, pregnant or nursing mothers, suspected pregnancy, or intention to become pregnant during the study;
- Residence in the same household as a subject already enrolled in the study (inclusion may create blinding and/or compliance issues);
- Unable and unwilling to comply with the informed consent process, to meet study requirements including following instructions on study intervention, and to return for follow-up visits as required by the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Iocide Oral Rinse
Iocide Oral Rinse once daily 30 second rinse for 24 weeks
|
Other Names:
|
Placebo Comparator: Placebo Control
Once daily 30 second rinse for 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Mean Gingival Index (GI)
Time Frame: Study Days -21 to -7 through Study Day 168
|
Study Days -21 to -7 through Study Day 168
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Biological Marker Data
Time Frame: Study Day 1, Day 28, Day 84 and Day 168
|
Study Day 1, Day 28, Day 84 and Day 168
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Product Safety
Time Frame: Study Days 1 through Study Days 168
|
The assessment of product safety will include the following: incidence of adverse events, measures of thyroid function, and iodine excretion.
Additionally, investigators will assess any development of opportunistic infection with Candida albicans, changes in oral tissues, and concomitant medication interactions.
|
Study Days 1 through Study Days 168
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Dolphus R Dawson III, DMD, MS, University of Kentucky
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Anticipated)
January 1, 2014
Study Completion (Anticipated)
May 1, 2014
Study Registration Dates
First Submitted
January 29, 2013
First Submitted That Met QC Criteria
January 30, 2013
First Posted (Estimate)
February 1, 2013
Study Record Updates
Last Update Posted (Estimate)
August 14, 2013
Last Update Submitted That Met QC Criteria
August 13, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UK12-0972-F2L
- R44HL101821 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gingivitis
-
Zainab J AbbasCompleted
-
University of SaskatchewanCompletedChronic Gingivitis | Chronic Gingivitis, Plaque InducedCanada
-
Tufts UniversityGuangdong Bixdo Health Technology Co., Ltd.Not yet recruitingPlaque Induced GingivitisUnited States
-
Cairo UniversityNot yet recruiting
-
Hospital Universiti Sains MalaysiaRecruitingGingivitis | Plaque Induced GingivitisMalaysia
-
Lander Enterprises, LLCCompletedPlaque Induced GingivitisUnited States
-
University of WashingtonColgate PalmoliveCompleted
-
Tokat Gaziosmanpasa UniversityAbant Izzet Baysal UniversityCompletedPregnancy Gingivitis
-
Maharishi Markendeswar University (Deemed to be...CompletedChronic GingivitisIndia
-
Ain Shams UniversityCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States